Fluid Challenges in Intensive Care
Launched by EUROPEAN SOCIETY OF INTENSIVE CARE MEDICINE · Feb 7, 2013
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Introduction
Fluid Administration in Critically Ill Patients.
Fluids are one of most common therapies used in critically ill patients. Fluids are the cornerstone of hemodynamic management. In overt bleeding, fluids are often given without guidance with specific haemodynamic monitoring. In other conditions when hypovolemia may be more subtle or when the response to fluids is more variable, fluids are often given in a more titrable way, monitoring their haemodynamic impact. This practice, called the fluid challenge technique has been proposed by Max Harry Weil more than 30 years ago \[1\].
...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All consecutive adult (18 years old and above) patients , up to a maximum of 20, in whom a fluid challenge is performed during a one week period will be included
- Exclusion Criteria:
- • 1/ Patient already included in the trial
- • 2/ Overt bleeding Patients younger than 18 year
About European Society Of Intensive Care Medicine
The European Society of Intensive Care Medicine (ESICM) is a leading professional organization dedicated to advancing the science and practice of intensive care medicine across Europe. Committed to improving patient outcomes, ESICM fosters collaborative research initiatives and clinical trials that address critical questions in intensive care. By bringing together healthcare professionals, researchers, and stakeholders, the society promotes evidence-based practices and innovative approaches to enhance the quality of care in critical settings. Through its rigorous scientific framework, ESICM aims to contribute significantly to the development and implementation of best practices in intensive care medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Trial Officials
Daniel De Backer, MD,PhD
Principal Investigator
Erasme University Hospital, Brussels
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials